NYSE:ABBVBiotechs
AbbVie (ABBV) Boosts Dividend After Net Income Slips—What Does This Reveal About Its Capital Priorities?
AbbVie reported third quarter 2025 earnings, highlighting increased sales of US$15.78 billion but a significant reduction in net income to US$186 million, alongside a US$847 million intangible asset impairment and a quarterly dividend increase to US$1.73 per share starting February 2026.
This combination of higher revenues, a large impairment charge, and a growing dividend illustrates the company’s intent to balance shareholder returns with financial discipline amid evolving business...